Lysophosphatidylcholine 18:2

Lysophosphatidylcholine 18:2 (1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC), a lysophospholipid, is a potential biomarker identified from insulin resistance (IR) polycystic ovary syndrome (PCOS) . Low plasma Lysophosphatidylcholine 18:2 also has been shown to predict impaired glucose tolerance, insulin resistance, type 2 diabetes, coronary artery disease, and memory impairment[1][2].

Product Specifications

CAS Number

[22252-07-9]

Product Name Alternative

1-Linoleoyl-2-Hydroxy-sn-glycero-3-PC; LPC (18:2/0:0) ; LysoPC (18:2)

UNSPSC

12352211

Hazard Statement

H302, H310, H315, H319, H331, H351, H361, H372

Target

Endogenous Metabolite

Type

Natural Products

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/lysophosphatidylcholine-18-2.html

Concentration

10mM

Purity

99.12

Solubility

DMSO : 40 mg/mL (ultrasonic) |Ethanol : ≥ 100 mg/mL

Smiles

CCCCC/C=C\C/C=C\CCCCCCCC(OC[C@@H](O)COP(OCC[N+](C)(C)C)([O-])=O)=O

Molecular Formula

C26H50NO7P

Molecular Weight

519.65

Precautions

H302, H310, H315, H319, H331, H351, H361, H372

References & Citations

[1]Gonzalez-Freire M, et al. Targeted Metabolomics Shows Low Plasma Lysophosphatidylcholine 18:2 Predicts Greater Decline of Gait Speed in Older Adults: The Baltimore Longitudinal Study of Aging. J Gerontol A Biol Sci Med Sci. 2019;74 (1) :62-67.|[2]Chen YX, et al. UHPLC/Q-TOFMS-based plasma metabolomics of polycystic ovary syndrome patients with and without insulin resistance. J Pharm Biomed Anal. 2016;121:141-150.